Teena diagnosed with cancer after noticing trousers had become too tight
Emily Clark, 16, from South Wales, was diagnosed with non-Hodgkin lymphoma after becoming bloated and noticing two hard lumps in her abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - June 2, 2014 Category: Consumer Health News Source Type: news

'My favourite jeans saved my life': Teenager is diagnosed with cancer after noticing her trousers had suddenly become too tight
Emily Clark, 16, from South Wales, was diagnosed with non-Hodgkin lymphoma after becoming bloated and noticing two hard lumps in her abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - June 2, 2014 Category: Consumer Health News Source Type: news

Karyopharm Provides Data Update for Selinexor in Non-Hodgkin's Lymphoma and Acute Myeloid Leukemia at 2014 ASCO Annual Meeting
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 31, 2014 Category: Pharmaceuticals Source Type: news

Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate
GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) support further development of polatuzumab vedotin (anti-CD79b ADC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 31, 2014 Category: Pharmaceuticals Source Type: news

New drug for non-Hodgkin lymphoma, chronic lymphocytic leukemia passes early test
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study. The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 23, 2014 Category: Science Source Type: news

New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
(Houston Methodist) A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 23, 2014 Category: Global & Universal Source Type: news

Hormone therapy linked to lower non-Hodgkin lymphoma risk
Menopausal hormone therapy use is linked to a lower risk of B-cell non-Hodgkin lymphoma, research has found. "The connection between lymphomas and menopausal hormone therapy use hinges on understanding the disease's biology and the window of susceptibility," the lead researcher said. "Hormone therapy is of interest because the loss of estrogen coupled with aging in women result in decreased immune function, which can elevate risk of non-Hodgkin lymphoma." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2014 Category: Science Source Type: news

Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. (Source: Roche Media News)
Source: Roche Media News - March 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - March 28, 2014 Category: Pharmaceuticals Source Type: news

Hepatitis C Infection and Higher Risk of Death From Non-liver CancersHepatitis C Infection and Higher Risk of Death From Non-liver Cancers
In addition to their increased risk of death from hepatocellular carcinoma, chronic hepatitis C virus (HCV)-infected patients also have a higher mortality rate from non-Hodgkin lymphoma and pancreatic, rectal, and oral and pharyngeal cancers. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2014 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Scientists explore promising new option for first line of attack in lymphoma
(University of Manchester) A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin's lymphoma -- a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 25, 2014 Category: Cancer & Oncology Source Type: news

Cleveland Clinic Studies Radiation-induced Mesothelioma
James Stevenson, M.D., renowned oncologist at the Cleveland Clinic, didn't need to see the recent study to know the face of malignant pleural mesothelioma was changing. He sees it in his waiting room all the time. While occupational exposure to asbestos, which is still the No. 1 cause of the rare disease, continues dropping significantly, the rate of mesothelioma remains steady. And the patients don't look the same anymore. Other causes, it seems, are emerging, and they may be rising. "The general thinking is that these non-asbestos related cases will increase as we move forward," said Stevenson, a mesothelio...
Source: Asbestos and Mesothelioma News - February 12, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Rise Expected in Radiation-Induced Mesothelioma
James Stevenson, M.D., renowned oncologist at the Cleveland Clinic, didn't need to see the recent study to know the face of malignant pleural mesothelioma was changing. He sees it in his waiting room all the time. While occupational exposure to asbestos, which is still the No. 1 cause of the rare disease, continues dropping significantly, the rate of mesothelioma remains steady. And the patients don't look the same anymore. Other causes, it seems, are emerging, and they may be rising. "The general thinking is that these non-asbestos related cases will increase as we move forward," said Stevenson, a mesothelio...
Source: Asbestos and Mesothelioma News - February 12, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

CHMP recommends EU approval of a new formulation of Roche’'s MabThera for patients with non-Hodgkin lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve MabThera (rituximab) 1400mg solution for subcutaneous (SC) injection for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Source: Roche Media News)
Source: Roche Media News - January 24, 2014 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of a new formulation of Roche’'s MabThera for patients with non-Hodgkin lymphoma
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve MabThera (rituximab) 1400mg solution for subcutaneous (SC) injection for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). “We are excited the MabThera SC data confirm the efficacy and safety of a significantly shortened treatment time,“ said Sandra Horning, M.D., Chief Medical Officer and Head, Global Product Development. “We are confident that reducing treatment to approximately five minutes with MabThera SC will be an improvement for patients...
Source: Roche Investor Update - January 24, 2014 Category: Pharmaceuticals Source Type: news

New drug shows promise in treating indolent non-Hodgkin lymphomas
(Fred Hutchinson Cancer Research Center) A new drug, idelalisib, showed promise in a phase 2 study for treating patients with indolent non-Hodgkin lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2014 Category: Cancer & Oncology Source Type: news

FDA accepts new drug application for Gilead's lymphoma drug Idelalisib
The US Food and Drug Administration (FDA) will review Gilead Sciences' new drug application (NDA) for idelalisib, an oral inhibitor of PI3K delta, to treat refractory indolent non-Hodgkin's lymphoma (iNHL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 16, 2014 Category: Pharmaceuticals Source Type: news

Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.The ongoing open-label phase 2 study presented at the American Society of Hematology (ASH) meeting was designed to test the activity of brentuximab vedotin (Adcetris) in relapsed or refractory non-Hodgkin lymphoma (NHL) including B-cell cancers such as diffuse large B cell lymphoma (DLBCL). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 12, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib
In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions reported at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation.Waldenstrom's is a form of non-Hodgkin lymphoma diagnosed in 2,000 to 3,000 people in the United States each year. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

A Case of Malignancy After Solid Organ TransplantationA Case of Malignancy After Solid Organ Transplantation
In this case, a child presents with non-Hodgkin lymphoma one year after an orthotropic heart transplant. What are the causes and risk factors of post-transplant malignancy? Journal of Pediatric Health Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Drug-antibody pair has promising activity in non-Hodgkin lymphoma
(Dana-Farber Cancer Institute) A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2013 Category: Global & Universal Source Type: news

TG Therapeutics starts first combination trial for treatment of CLL and NHL patients
TG Therapeutics has started a multi-centre, Phase I trial of the combination of TG-1101 (ublituximab) and TGR-1202 in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - November 27, 2013 Category: Pharmaceuticals Source Type: news

ASH 2013: Big Year for CLL, LymphomaASH 2013: Big Year for CLL, Lymphoma
Highlighting major studies and a plethora of new drugs, Dr. Bruce Cheson predicts that ASH 2013 will be a big year for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Pushing 80 and given two weeks to live, dying patient cures by cannabis
Stan and Barb Rutner had already had bouts with cancer earlier in their lives. Barb overcame breast cancer with orthodox treatments and her version of visualization twice. And Stan managed to get through non-Hodgkin lymphoma after six months of treatment. But this time... (Source: NaturalNews.com)
Source: NaturalNews.com - November 20, 2013 Category: Consumer Health News Source Type: news

Burkitt's Yields to Longer-Duration, Lower-Dose ChemoBurkitt's Yields to Longer-Duration, Lower-Dose Chemo
Length of exposure to cytotoxic therapy appears to be at least as important as drug-dose intensity in the treatment of Burkitt's, the most aggressive form of non-Hodgkin's lymphoma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves Imbruvica for rare blood cancer
The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.MCL is a rare form of non-Hodgkin lymphoma and represents about 6 percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diagnosed, it usually has already spread to the lymph nodes, bone marrow and other organs.Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 15, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

U.S. health regulators approve J&J, Pharmacyclics lymphoma drug
(Reuters) - U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson & Johnson and Pharmacyclics Inc, marking the second drug that received the FDA's new breakthrough therapy designation to gain approval. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Study evaluates early stem cell transplants for non-Hodgkin's lymphoma
Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found. Lead author is Patrick Stiff, MD, director of Loyola University Medical Center's Cardinal Bernardin Cancer Center. The study was developed by the SWOG cancer research cooperative group and funded by the National Cancer Institute... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma Patients
Study found increased survival rate but only for those with highest-risk diseaseSource: HealthDay Related MedlinePlus Pages: Lymphoma, Stem Cells (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 31, 2013 Category: Consumer Health News Source Type: news

Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma Patients
Title: Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma PatientsCategory: Health NewsCreated: 10/31/2013 9:35:00 AMLast Editorial Review: 10/31/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 31, 2013 Category: Cancer & Oncology Source Type: news

Stem-Cell Therapy Misses Mark in Lymphoma Trial (CME/CE)
(MedPage Today) -- Progression of aggressive non-Hodgkin's lymphoma slowed significantly after autologous stem-cell transplantation, although overall survival did not improve, according to results of a randomized trial. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 30, 2013 Category: Hematology Source Type: news

NEJM study evaluates early stem cell transplants for non-Hodgkin's lymphoma
(Loyola University Health System) Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 30, 2013 Category: Cancer & Oncology Source Type: news

'Ozone therapy' endangered patient's life, court hears
A retired GP put his patient's life at risk performing a 'bizarre' alternative therapy with no proven benefits to treat a rare form of non-Hodgkins lymphoma, a tribunal heard     (Source: Telegraph Health)
Source: Telegraph Health - October 21, 2013 Category: Consumer Health News Source Type: news

NDA Filed for Idelalisib for Treating Non-Hodgkin Lymphoma
Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy. (Source: Cancer Network)
Source: Cancer Network - September 18, 2013 Category: Cancer & Oncology Source Type: news

'No link' between nuclear plants and child cancer
This report suggested that there were more cases of cancer than expected in young people in the vicinity of what is now known as the Sellafield nuclear power plant. This led to the setting up of the Committee on Medical Aspects of Radiation in the Environment (COMARE), which analyses data on rates of cancer in children in the areas around nuclear plants in Great Britain. A report from COMARE in 2005 found that although a number of excess cases of some kinds of childhood cancer were found for nuclear sites whose main function was not the generation of electricity they “found no evidence of excess numbers of cases in a...
Source: NHS News Feed - September 13, 2013 Category: Consumer Health News Tags: Cancer Source Type: news

Nuclear plants don't raise child leukaemia risk: study
LONDON (Reuters) - Despite fears to the contrary, children who live near nuclear power plants have no greater risk of developing leukaemia or a type of cancer known as non-Hodgkin lymphoma, according to a large British study published on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Nuclear Plants Don't Raise Child Leukemia Risk
Despite fears to the contrary, children who live near nuclear power plants have no greater risk of developing leukaemia or a type of cancer known as non-Hodgkin lymphoma, according to a large British study published on Friday.Source: Reuters Health Related MedlinePlus Pages: Childhood Leukemia, Radiation Exposure (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 13, 2013 Category: Consumer Health News Source Type: news

Gilead files NDA of idelalisib with FDA for treatment of indolent non-Hodgkin’s lymphoma
US biotechnology firm Gilead Sciences has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for approval of idelalisib, an investigational drug for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2013 Category: Pharmaceuticals Source Type: news

Microbiota Predict Chemotherapy-Induced DiarrheaMicrobiota Predict Chemotherapy-Induced Diarrhea
For the first time, researchers have linked changes in gut microbiota and chemotherapy-induced diarrhea in patients with non-Hodgkin's lymphoma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Actelion close to sealing Ceptaris deal as US approves drug
The US health regulator FDA has approved Ceptaris Therapeutics' topical drug for treatment of a rare form of non-Hodgkin's lymphoma, Actelion said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 26, 2013 Category: Pharmaceuticals Source Type: news

Novel drug shuts down master protein key to lymphoma
(Weill Cornell Medical College) Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2013 Category: Global & Universal Source Type: news

No improvement seen in HIV-associated lymphoma survival during the antiretroviral therapy era
Stable survival rates were observed for HIV-associated lymphoma patients during the antiretroviral therapy (ART) era in the US, according to a new study published in the Journal of the National Cancer Institute. Studies have shown that HIV infection increases the risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) and that incidence for many lymphoma types has not decreased in the ART era. Furthermore, lymphoma is the most frequent cancer-related cause of death among HIV-infected persons... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 30, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Mapping Link Between Blood Cancer, Industrial Pollutant in Georgia
Benzene appears to raise risk of non-Hodgkin lymphoma, researchers say (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - July 30, 2013 Category: Cancer & Oncology Source Type: news

Living near industrial plant may raise risk of non-Hodgkin lymphoma
Cancer risk dropped 0.31 percent for every mile further away person lived from benzene-producing facility in Georgia (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 29, 2013 Category: Consumer Health News Source Type: news

Benzene Exposure Linked to Increased Rate of NHLBenzene Exposure Linked to Increased Rate of NHL
Populations living close to sites that release benzene into the environment have higher rates of non-Hodgkin's lymphoma (NHL), suggesting an association. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mapping Link Between Blood Cancer, Industrial Pollutant in Georgia
Benzene appears to raise risk of non-Hodgkin lymphoma, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 29, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Oncology, News, Source Type: news

Higher Cancer Incidences Found in Regions Near Refineries and Plants that Release Benzene
The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer. Non-Hodgkin lymphoma has been on the rise over the past few decades as industrial production in the United States has expanded... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin Lymphoma
The phase II portion of the GAUGUIN study found promising activity with the anti-CD20 antibody obinutuzumab in patients with relapsed or refractory indolent NHL. (Source: Cancer Network)
Source: Cancer Network - July 22, 2013 Category: Cancer & Oncology Source Type: news

Oil Worker Abandons Radiation Theory But Defends Benzene Claims
NEW ORLEANS - An oil and gas field worker alleging injury from exposure to benzene opposes partial summary judgment but acknowledges in a June 18 brief in Louisiana federal court that he has abandoned a theory that radioactivity in the petroleum distillates he handled contributed to his non-Hodgkin's lymphoma (Chris Cologne, et uxor v. Shell Oil Co., et al., No. 12-735, E.D. La.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 4, 2013 Category: Medical Law Source Type: news

Second Draft NICE Guidance For Aggressive Non-Hodgkin Lymphoma Treatment, PIXUVRI® (Pixantrone)
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) have announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued a second draft guidance on the use of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news